Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta ‐analysis
ConclusionsThis meta-analysis demonstrates thatFCGR3A V allele carriers show better responsiveness to rituximab, andFCGR2A R allele carriers may show a better response to biologics in RA treatment. Genotyping of these polymorphisms could be a useful tool to find associations with the responsiveness of personalized medicine to biologics. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - April 28, 2023 Category: Rheumatology Authors: Young Ho Lee,
Gwan Gyu Song Tags: ORIGINAL ARTICLE Source Type: research
Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study
Int J Mol Sci. 2023 Apr 9;24(8):6967. doi: 10.3390/ijms24086967.ABSTRACTRheumatoid arthritis (RA) patients on JAK inhibitors (JAKi) have an increased HZ risk compared to those on biologic DMARDs (bDMARDs). Recently, the Adjuvanted Recombinant Zoster Vaccine (RZV) became available worldwide, showing good effectiveness in patients with inflammatory arthritis. Nevertheless, direct evidence of the immunogenicity of such a vaccine in those on JAKi or anti-cellular bDMARDs is still lacking. This prospective study aimed to assess RZV immunogenicity and safety in RA patients receiving JAKi or anti-cellular bDMARDs that are known t...
Source: Herpes - April 28, 2023 Category: Infectious Diseases Authors: Vincenzo Venerito Pasquale Stefanizzi Luca Cantarini Marlea Lavista Maria Grazia Galeone Antonio Di Lorenzo Florenzo Iannone Silvio Tafuri Giuseppe Lopalco Source Type: research
Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study
Int J Mol Sci. 2023 Apr 9;24(8):6967. doi: 10.3390/ijms24086967.ABSTRACTRheumatoid arthritis (RA) patients on JAK inhibitors (JAKi) have an increased HZ risk compared to those on biologic DMARDs (bDMARDs). Recently, the Adjuvanted Recombinant Zoster Vaccine (RZV) became available worldwide, showing good effectiveness in patients with inflammatory arthritis. Nevertheless, direct evidence of the immunogenicity of such a vaccine in those on JAKi or anti-cellular bDMARDs is still lacking. This prospective study aimed to assess RZV immunogenicity and safety in RA patients receiving JAKi or anti-cellular bDMARDs that are known t...
Source: Herpes - April 28, 2023 Category: Infectious Diseases Authors: Vincenzo Venerito Pasquale Stefanizzi Luca Cantarini Marlea Lavista Maria Grazia Galeone Antonio Di Lorenzo Florenzo Iannone Silvio Tafuri Giuseppe Lopalco Source Type: research
Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis
AbstractActive rheumatoid arthritis (RA) is associated with increased cardiovascular risk and impaired function of high-density lipoprotein (HDL). Previous work suggests that HDL may become dysfunctional through oxidative modifications within the RA joint. The current work evaluates an association of synovial power doppler ultrasound signal (PDUS) with HDL function and structure. Two open-label clinical therapeutic studies using PDUS as a disease outcome measure were included in this analysis, including a 12-month trial of subcutaneous abatacept in 24 RA patients and a 6-month trial of IV tocilizumab in 46 RA patients. Lab...
Source: Rheumatology International - April 25, 2023 Category: Rheumatology Source Type: research
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study
AVERT-2 (a phase IIIb, two-stage study) evaluated abatacept + methotrexate versus methotrexate alone, in methotrexate-naive, anti-citrullinated protein antibody-positive patients with early (≤ 6 months), activ... (Source: Arthritis Research and Therapy)
Source: Arthritis Research and Therapy - April 22, 2023 Category: Rheumatology Authors: Paul Emery, Yoshiya Tanaka, Vivian P. Bykerk, Clifton O. Bingham, Thomas W. J. Huizinga, Gustavo Citera, Kuan-Hsiang Gary Huang, Chun Wu, Sean E. Connolly, Yedid Elbez, Robert Wong, Karissa Lozenski and Roy Fleischmann Tags: Research Source Type: research
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
Nature Reviews Clinical Oncology, Published online: 11 April 2023; doi:10.1038/s41571-023-00762-1Immune-checkpoint-inhibitor-associated myocarditis has a high fatality rate, warranting the development of more-effective treatment strategies. Herein, we discuss a recent report of a series of patients who were managed using a novel approach that involved personalized abatacept dosing, ruxolitinib and close respiratory monitoring, which was associated with low mortality. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 11, 2023 Category: Cancer & Oncology Authors: Douglas B. Johnson Alexander M. Menzies Source Type: research
GSE224842 Gene expression profiles of peripheral blood mononuclear cells before abatacept treatment in rheumatoid arthritis patients.
Contributors : Shigeru Tanaka ; Hiroshi NakajimaSeries Type : Expression profiling by arrayOrganism : Homo sapiensTo explore markers which predict the efficacy of abatacept in rheumatoid arthritis, peripheral blood mononuclear cells were obtained before abatacept treatment. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 10, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Immune-mediated Necrotizing Myositis Associated Fulminant Myocarditis Recovered On Peripheral Veno-arterial Extracorporeal Membrane Oxygenation
A 41-year-old male with anti-signal recognition particle (SRP) positive immune-mediated necrotizing myositis (IMNM) on abatacept, prednisone, and subcutaneous immune globulin previously refractory to conventional diseases modifying antirheumatic drugs and biologic agents (intravenous immune globulin, azathioprine, methotrexate, tacrolimus, rituximab) presented for shortness of breath and right sided chest pain. He was found to have new onset atrial flutter with 2:1 conduction. Chest CTA demonstrated multiple right sided segmental pulmonary emboli. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Zackary Tushak, Kerianne Fullin, Javier Farinas, Rachael Gordon, Timothy Wong, Jessica Huston, Mary Keebler, Dennis McNamara, Michael Mathier, David Kaczorowski, Christina Thorngren, Birru Talabi Mehret, Gavin Hickey Tags: 360 Source Type: research
Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives
Expert Rev Clin Immunol. 2023 Mar 30. doi: 10.1080/1744666X.2023.2198208. Online ahead of print.ABSTRACTINTRODUCTION: Patients with Common variable immunodeficiency (CVID) have a high frequency of inflammatory complications like autoimmune cytopenias, interstitial lung disease and enteropathy. These patients have poor prognosis and effective, timely and safe treatment of inflammatory complications in CVID are essential, but guidelines and consensus on therapy are often lacking.AREAS COVERED: This review will focus on current medical treatment of inflammatory complications in CVID and point out some future perspectives base...
Source: Expert Review of Clinical Immunology - March 30, 2023 Category: Allergy & Immunology Authors: B ørre Fevang Source Type: research
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial
CONCLUSIONSAlthough abatacept treatment for 1 year did not significantly delay progression to glucose intolerance in at-risk individuals, it impacted immune cell subsets and preserved insulin secretion, suggesting that costimulation blockade may modify progression of type 1 diabetes. (Source: Diabetes Care)
Source: Diabetes Care - March 15, 2023 Category: Endocrinology Source Type: research
Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis
CONCLUSIONS: This meta-analysis concludes that in adult with rheumatoid arthritis, abatacept can achieve better health outcomes than other biologic drugs.PMID:36912326 | DOI:10.55563/clinexprheumatol/2xjg0d (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 13, 2023 Category: Rheumatology Authors: Mariame Mohamed Ahamada Xiaochuan Wu Source Type: research
GSE224330 Gene expression of monocytes from rheumatoid arthritis patients treated with bDMARDs and methotrexate.
Contributors : Luigia G Fresu ; Federico A Ruffinatti ; Maria TalmonSeries Type : Expression profiling by arrayOrganism : Homo sapiensIt is well documented that patients affected by rheumatoid arthritis (RA) have distinct susceptibility to the different biologic Disease-Modifying AntiRheumatic Drugs (bDMARDs) available on the market, probably because of the many facets of the disease. Monocytes are deeply involved in the pathogenesis of RA and we therefore evaluated and compared the transcriptomic profile of monocytes isolated from patients on treatment with methotrexate alone or in combination with tocilizumab, anti-TNFa...
Source: GEO: Gene Expression Omnibus - March 9, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
